Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Holdings Raised by Wellington Management Group LLP

Wellington Management Group LLP grew its stake in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 2.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,197,546 shares of the biotechnology company’s stock after purchasing an additional 174,716 shares during the period. Wellington Management Group LLP owned about 9.06% of Rocket Pharmaceuticals worth $245,680,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of RCKT. Annandale Capital LLC acquired a new position in Rocket Pharmaceuticals during the third quarter valued at $66,000. Tower Research Capital LLC TRC raised its position in Rocket Pharmaceuticals by 105.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,557 shares of the biotechnology company’s stock valued at $107,000 after buying an additional 1,829 shares during the period. Old Well Partners LLC acquired a new position in Rocket Pharmaceuticals during the fourth quarter valued at $200,000. Capstone Investment Advisors LLC acquired a new position in Rocket Pharmaceuticals during the fourth quarter valued at $217,000. Finally, Amalgamated Bank raised its position in Rocket Pharmaceuticals by 5.4% during the fourth quarter. Amalgamated Bank now owns 8,653 shares of the biotechnology company’s stock valued at $259,000 after buying an additional 440 shares during the period. 98.39% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on RCKT shares. JPMorgan Chase & Co. dropped their price target on Rocket Pharmaceuticals from $55.00 to $50.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 27th. William Blair reaffirmed an “outperform” rating on shares of Rocket Pharmaceuticals in a research report on Monday, June 3rd. UBS Group dropped their target price on Rocket Pharmaceuticals from $56.00 to $54.00 and set a “buy” rating on the stock in a research report on Friday, March 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $53.00 target price on shares of Rocket Pharmaceuticals in a research report on Tuesday, May 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 target price on shares of Rocket Pharmaceuticals in a research report on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $52.13.

Insider Activity at Rocket Pharmaceuticals

In related news, Director Gotham Makker sold 274,000 shares of the stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $28.43, for a total transaction of $7,789,820.00. Following the completion of the sale, the director now owns 365,912 shares in the company, valued at approximately $10,402,878.16. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Gotham Makker sold 274,000 shares of the stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $28.43, for a total transaction of $7,789,820.00. Following the completion of the sale, the director now owns 365,912 shares in the company, valued at approximately $10,402,878.16. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Gaurav Shah sold 9,790 shares of the stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $23.35, for a total value of $228,596.50. Following the sale, the chief executive officer now owns 728,069 shares of the company’s stock, valued at approximately $17,000,411.15. The disclosure for this sale can be found here. Insiders sold a total of 381,772 shares of company stock worth $10,411,590 in the last 90 days. 31.10% of the stock is owned by company insiders.

Rocket Pharmaceuticals Stock Performance

Shares of NASDAQ RCKT opened at $20.68 on Wednesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 10.47 and a current ratio of 10.47. The firm has a market cap of $1.88 billion, a price-to-earnings ratio of -7.21 and a beta of 1.08. The business’s 50-day simple moving average is $22.71 and its 200-day simple moving average is $26.19. Rocket Pharmaceuticals, Inc. has a 52 week low of $14.89 and a 52 week high of $32.53.

Rocket Pharmaceuticals (NASDAQ:RCKT) last issued its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.01. During the same period last year, the business posted ($0.73) EPS. As a group, equities research analysts expect that Rocket Pharmaceuticals, Inc. will post -2.85 earnings per share for the current fiscal year.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.